Back to top
more

OncoMed Pharmaceuticals, Inc. (OMED)

(Delayed Data from NSDQ)

$0.89 USD

0.89
NA

0.00 (0.00%)

Updated Apr 22, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

OncoMed Pharmaceuticals (OMED) Q3 Earnings Preview: How Are Events Shaping Up?

by Zacks Equity Research

OncoMed (OMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OncoMed (OMED) delivered earnings and revenue surprises of 56.52% and -8.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y

    by Zacks Equity Research

    Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.

      Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y

      by Zacks Equity Research

      Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.

        Debapriya Chakraborty headshot

        Pick 3 Biotech Money-Spinning Bets Amid Market Instability

        by Debapriya Chakraborty

        The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

          Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?

          by Zacks Equity Research

          Investors certainly have to be happy with OncoMed Pharmaceuticals, Inc. (OMED) and its short term performance

            Joseph Lu headshot

            Here's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today

            by Joseph Lu

            Shares of OncoMed Pharmaceuticals Inc. (OMED) closed the day down 3.74% to $3.86 per share. The plunge came after both JMP (JMP) and Piper Jaffray (PJC) downgraded the company???s rating.

              OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal

              by Zacks Equity Research

              It was a bad day for OncoMed Pharmaceuticals, Inc. (OMED) as it suffered two setbacks.

                Are Options Traders Betting on a Big Move in OncoMed Pharmaceuticals (OMED) Stock?

                by Zacks Equity Research

                OncoMed Pharmaceuticals (OMED) warrants investors' attention based on moves in the options market lately.

                  Amanda Priyanka Gomes headshot

                  Are Options Traders Betting on a Big Move in OncoMed (OMED) Stock?

                  by Amanda Priyanka Gomes

                  Options traders are pricing in a big move for OncoMed (OMED) shares as it has huge implied volatility.